Alectinib hydrochloride
98%
- Product Code: 99473
CAS:
1256589-74-8
| Molecular Weight: | 519.08 g./mol | Molecular Formula: | C₃₀H₃₄N₄O₂HCl |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃ |
Product Description:
Alectinib hydrochloride is primarily used in the treatment of non-small cell lung cancer (NSCLC), specifically for patients whose cancer is anaplastic lymphoma kinase (ALK)-positive. It works by inhibiting the activity of the ALK protein, which is involved in the growth and spread of cancer cells. This targeted therapy is effective in slowing or stopping the progression of the disease, particularly in cases where the cancer has metastasized to the brain. It is often prescribed when other ALK inhibitors, such as crizotinib, have failed or are no longer effective. The drug is administered orally, making it convenient for patients to use as part of their ongoing treatment regimen. Its ability to cross the blood-brain barrier also makes it a valuable option for managing brain metastases associated with ALK-positive NSCLC.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | White to Off-White Solid |
| PURITY | 97.5-100 |
| Infrared spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | ฿4,700.00 |
+
-
|
| 0.025 | 10-20 days | ฿12,290.00 |
+
-
|
Alectinib hydrochloride
Alectinib hydrochloride is primarily used in the treatment of non-small cell lung cancer (NSCLC), specifically for patients whose cancer is anaplastic lymphoma kinase (ALK)-positive. It works by inhibiting the activity of the ALK protein, which is involved in the growth and spread of cancer cells. This targeted therapy is effective in slowing or stopping the progression of the disease, particularly in cases where the cancer has metastasized to the brain. It is often prescribed when other ALK inhibitors, such as crizotinib, have failed or are no longer effective. The drug is administered orally, making it convenient for patients to use as part of their ongoing treatment regimen. Its ability to cross the blood-brain barrier also makes it a valuable option for managing brain metastases associated with ALK-positive NSCLC.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :